[ Return to Index ]

Oncolytics issued Canadian reovirus patent

Oncolytics Biotech, Inc. (Calgary, Canada) has been granted Canadian Patent 2,428,206 entitled "Methods for the treatment of cellular proliferative disorders." The claims describe methods of treating various types of cellular proliferative disorders including neurofibromatosis and neoplasms by the administration of various strains of the reovirus.

"The claims in Oncolytics' second Canadian patent provide broad coverage for the use of reovirus in treating cellular proliferative disorders including cancers," said Dr. Matt Coffey, Chief Scientific Officer for Oncolytics. "This patent complements existing intellectual property coverage of reovirus for the treatment of various human cancers in the U.S., Europe and worldwide."

Oncolytics is focused on the development of REOLYSIN, its proprietary formulation of the human reovirus, as a potential cancer therapeutic. Oncolytics' researchers have demonstrated that the reovirus is able to selectively kill cancer cells and, in vitro, kill human cancer cells that are derived from many types of cancer including breast, prostate, pancreatic, bladder and brain tumors, and have also demonstrated successful cancer treatment results in a number of animal models. Phase I clinical trial results have indicated that REOLYSIN was well tolerated and that the reovirus demonstrated activity in tumors injected with REOLYSIN. Oncolytics has developed a strategy to pursue the licensing of its Canadian patents for research, development and commercial activities. Oncolytics has established a form and terms for licenses with individuals and institutions wishing to conduct academic research and will be negotiating appropriate licenses with individuals, institutions and companies involved in other activities in Canada.

Oncolytics Biotech, Inc.
+1-403-670-7377
www.oncolyticsbiotech.com